循环微RNA：神经母细胞瘤诊断生物标志物的新候选者。
Circulating microRNA: a new candidate for diagnostic biomarker in neuroblastoma.
作者信息
Mohammadi M, Goodarzi M, Jaafari M R, Mirzaei H R, Mirzaei H
机构信息
Hepatitis Research Center and Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Lorestan University of Medical Sciences, Khorramabad, Iran.
Department of Biosystems, Faculty of Bioscience Engineering, Katholieke Universiteit Leuven-KU Leuven, Heverlee, Belgium.
出版信息
Cancer Gene Ther. 2016 Nov;23(11):371-372. doi: 10.1038/cgt.2016.45. Epub 2016 Oct 14.
Neuroblastoma (NB) is known as a pediatric neoplasm that is associated with variable histopathological features. The use of biomarkers contributes to the monitoring and treatment of various malignancies such as NB. The identification of novel biomarkers such as (epi)genetic biomarkers and microRNAs (miRNAs) in NB has led to better treatments of NB. Among them, miRNAs have emerged as powerful tools in diagnosis, prognosis and therapeutic biomarkers for patients with NB. Circulating biomarkers such as circulating miRNAs present in body fluids (for example, plasma, serum and urine) provided an interesting field of study in NB treatment. The miRNAs have central roles in different pathogenic events in various malignancies such as NB. Hence, these molecules can be a suitable candidate for monitoring and treating NB patients. Here, we summarize some miRNAs as potential prognosis, diagnosis and therapeutic biomarkers in NB.
神经母细胞瘤（NB）是一种与多种组织病理学特征相关的儿科肿瘤。生物标志物的使用有助于监测和治疗诸如NB等各种恶性肿瘤。在NB中鉴定新型生物标志物，如（表观）遗传生物标志物和微小RNA（miRNA），已带来了对NB更好的治疗方法。其中，miRNA已成为NB患者诊断、预后和治疗生物标志物的有力工具。体液（如血浆、血清和尿液）中存在的循环生物标志物，如循环miRNA，为NB治疗提供了一个有趣的研究领域。miRNA在诸如NB等各种恶性肿瘤的不同致病事件中发挥着核心作用。因此，这些分子可能是监测和治疗NB患者的合适候选物。在此，我们总结了一些miRNA作为NB潜在的预后、诊断和治疗生物标志物。
Zotero 插件